SELECT: Novo Nordisk Comes Roaring Back

 
• By Elizabeth Cairns

After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.  

Novo Nordisk Headquarters

More from Cardiovascular

More from Therapy Areas